While Acadia Pharmaceuticals Inc has overperformed by 1.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACAD fell by -2.13%, with highs and lows ranging from $33.99 to $17.56, whereas the simple moving average fell by -26.74% in the last 200 days.
On March 12, 2024, Needham Reiterated Acadia Pharmaceuticals Inc (NASDAQ: ACAD) to Buy. A report published by Mizuho on March 12, 2024, Downgraded its rating to ‘Neutral’ for ACAD. Robert W. Baird also rated ACAD shares as ‘Outperform’, setting a target price of $40 on the company’s shares in an initiating report dated January 30, 2024. Morgan Stanley December 19, 2023d its ‘Equal-Weight’ rating to ‘Overweight’ for ACAD, as published in its report on December 19, 2023. Deutsche Bank’s report from December 14, 2023 suggests a price prediction of $25 for ACAD shares, giving the stock a ‘Hold’ rating. Citigroup also rated the stock as ‘Buy’.
Analysis of Acadia Pharmaceuticals Inc (ACAD)
Further, the quarter-over-quarter increase in sales is 69.27%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Acadia Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -14.73% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.28, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ACAD is recording an average volume of 1.86M. On a monthly basis, the volatility of the stock is set at 3.58%, whereas on a weekly basis, it is put at 2.74%, with a gain of 3.54% over the past seven days. Furthermore, long-term investors anticipate a median target price of $29.31, showing growth from the present price of $18.42, which can serve as yet another indication of whether ACAD is worth investing in or should be passed over.
How Do You Analyze Acadia Pharmaceuticals Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 97.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACAD shares are owned by institutional investors to the tune of 97.14% at present.
